Sema4: A Patient-Centered Health Intelligence Company

Advancing Healthcare

through data-driven insights

A Health Intelligence Company That Puts Patients in the Center

Sema4 is founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.

Learn more

Centrellis™

Our unique analytics platform, Centrellis, allows us to offer advanced tools to help providers better manage data for patient populations, launch new clinical studies, and easily compare patient outcomes across a healthcare system.

Learn more

Women’s Health

From pregnancy planning to expanded carrier screening, we deploy robust science and cutting-edge tools to give patients more actionable information all along the family journey through advanced genomic testing.

Learn more

Precision Oncology

Our family of precision oncology products and services, Sema4 Signal™, provides data-driven care solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.

Learn more

Biopharma

Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.

Learn more

Robust Research

Sema4’s accomplished research team includes world leaders in data science, machine learning, network modeling, and genomics. We’ve published more than 150 peer-reviewed papers and remain committed to providing science-driven solutions to the most pressing medical needs.

Learn more

Latest News

November 15th, 2021

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights

Sema4 reported the financial results for the third quarter ended September 30, 2021 and provided an update on key strategic and operational initiatives.

November 4th, 2021

Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction

Sema4 has published two studies in collaboration with the Mount Sinai Health System, which could significantly advance outcomes for postpartum hemorrhage, a preventable life-threatening emergency responsible for 35% of maternal deaths.

September 13th, 2021

Sema4 Appoints Gustavo Stolovitzky, Computational Biology Expert, as Chief Science Officer

Sema4 appointed Gustavo Stolovitzky, PhD, to the newly established senior leadership position of Chief Science Officer (CSO). Dr. Stolovitzky is a world-renowned expert in computational biology, algorithm development, and disease modeling.

Featured In

Awards and Recognition